Alireza Kashefizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alireza Kashefizadeh has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Amir Behnam Kharazmi
Department of Internal Medicine, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Alireza Kashefizadeh2 shared publications
- Aminollah Vasigh
Department of Neurology, School of Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Atefeh Abedini
Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
2 shared publications - Akbar Soleimani
Department of Internal Medicine, School of Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran
1 shared publication - Ali Ahmadi
Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran
1 shared publication
Latest Publications
- 29 December 2025
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 27 (4) , 146-151
Comparing the Effects of Oral Azithromycin with Standard Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Double-Blind Randomized Controlled Trial
Background and aims: Data regarding the use of macrolide antibiotics in patients with chronic obstructive pulmonary disease (COPD) are limited and inconsistent. The objective of this study was to evaluate the effectiveness of adding azithromycin to the standard treatment regimen for patients with COPD. Methods: In this clinical trial, 100 patients with COPD who were referred to the clinic and teaching hospitals of Shahrekord were divided into two groups. In addition to standard triple therapy (inhaled anticholinergic, inhaled bronchodilator, and inhaled corticosteroids), the experimental group received oral azithromycin at a dosage of 250 mg daily for two months. The control group received a placebo in conjunction with standard triple therapy. Both groups were assessed before and after the intervention using spirometry, blood oxygen saturation measurements, and the severity of dyspnea based on the Modified Medical Research Council (MMRC) criteria, as well as treatment outcomes. The data were analyzed using SPSS 22.0. Results: Following the intervention, the mean forced expiratory volume in one second (FEV1) increased by 4.28 (95% confidence interval [CI]: 3.93 to 4.63) in the intervention group compared to an increase of 3.78 (95% CI: 3.43 to 4.13) in the control group (P=0.004). The mean oxygen saturation improved by 4.88% (95% CI: 4.53 to 5.23) in the intervention group as opposed to an increase of 4.28% (95% CI: 3.93 to 4.63) in the control group (P=0.006). However, the MMRC score decreased by -0.82 (95% CI: -0.92 to -0.72) in the intervention group compared to a decrease of -0.54 (95% CI: -0.64 to -0.44) in the control group (P=0.002). Conclusion: The administration of azithromycin in conjunction with standard treatment demonstrated significantly improved outcomes compared to standard treatment alone.
- 29 December 2025
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 27 (4) , 146-151
Comparing the Effects of Oral Azithromycin with Standard Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Double-Blind Randomized Controlled Trial
Background and aims: Data regarding the use of macrolide antibiotics in patients with chronic obstructive pulmonary disease (COPD) are limited and inconsistent. The objective of this study was to evaluate the effectiveness of adding azithromycin to the standard treatment regimen for patients with COPD. Methods: In this clinical trial, 100 patients with COPD who were referred to the clinic and teaching hospitals of Shahrekord were divided into two groups. In addition to standard triple therapy (inhaled anticholinergic, inhaled bronchodilator, and inhaled corticosteroids), the experimental group received oral azithromycin at a dosage of 250 mg daily for two months. The control group received a placebo in conjunction with standard triple therapy. Both groups were assessed before and after the intervention using spirometry, blood oxygen saturation measurements, and the severity of dyspnea based on the Modified Medical Research Council (MMRC) criteria, as well as treatment outcomes. The data were analyzed using SPSS 22.0. Results: Following the intervention, the mean forced expiratory volume in one second (FEV1) increased by 4.28 (95% confidence interval [CI]: 3.93 to 4.63) in the intervention group compared to an increase of 3.78 (95% CI: 3.43 to 4.13) in the control group (P=0.004). The mean oxygen saturation improved by 4.88% (95% CI: 4.53 to 5.23) in the intervention group as opposed to an increase of 4.28% (95% CI: 3.93 to 4.63) in the control group (P=0.006). However, the MMRC score decreased by -0.82 (95% CI: -0.92 to -0.72) in the intervention group compared to a decrease of -0.54 (95% CI: -0.64 to -0.44) in the control group (P=0.002). Conclusion: The administration of azithromycin in conjunction with standard treatment demonstrated significantly improved outcomes compared to standard treatment alone.
- 29 July 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (1) , e43926
Effectiveness of inhaled corticosteroids on COPD exacerbation rates based on serum eosinophil count; a prospective cohort study
Introduction: Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory condition characterized by chronic inflammation and exacerbations. Inhaled corticosteroids (ICS) are commonly prescribed to reduce exacerbation risk, yet their efficacy varies among patients. Emerging evidence suggests that blood eosinophil count may serve as a biomarker to predict ICS responsiveness in COPD patients. Objectives: This study investigates the relationship between serum eosinophil counts and the effectiveness of ICS in reducing COPD exacerbation rates. Patients and Methods: This prospective cohort study enrolled 430 COPD patients from two major pulmonology centers in Tehran, Iran, between May 2021 and November 2022. After obtaining written informed consent, demographic data and spirometry measurements were collected to classify COPD severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. Venous blood samples were analyzed for eosinophil counts, categorizing patients into groups with counts below or above 300 cells/μL. Participants were followed for six months to record clinical outcomes, including mortality, hospitalizations, and outpatient visits related to COPD exacerbations. The study’s primary focus was to assess the impact of ICS on exacerbation rates stratified by eosinophil levels, aiming to evaluate eosinophil count as a biomarker for treatment responsiveness and to inform personalized COPD management. Results: In a population of COPD patients who underwent ICS, the results indicated that patients with eosinophil counts higher than 300 cells/μL, compared to those with lower counts, demonstrated significantly fewer hospitalization rates (unadjusted B: -0.52 and adjusted B: -0.55). Similarly, the relationship between elevated eosinophil counts and outpatient visit frequency showed significant negative associations (unadjusted B: -1.82 and adjusted B: 1.88). However, in terms of six-month outcomes (recovery versus death), no statistically significant differences were observed between the two groups. Conclusion: These findings suggest that blood eosinophil counts ≥300 cells/μL are associated with a pronounced reduction in severe COPD exacerbations among patients treated with ICS. This supports the use of eosinophil levels as a practical biomarker to guide ICS therapy, enabling more targeted, personalized treatment strategies that optimize clinical outcomes in COPD management.
- 29 July 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (1) , e43926
Effectiveness of inhaled corticosteroids on COPD exacerbation rates based on serum eosinophil count; a prospective cohort study
Introduction: Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory condition characterized by chronic inflammation and exacerbations. Inhaled corticosteroids (ICS) are commonly prescribed to reduce exacerbation risk, yet their efficacy varies among patients. Emerging evidence suggests that blood eosinophil count may serve as a biomarker to predict ICS responsiveness in COPD patients. Objectives: This study investigates the relationship between serum eosinophil counts and the effectiveness of ICS in reducing COPD exacerbation rates. Patients and Methods: This prospective cohort study enrolled 430 COPD patients from two major pulmonology centers in Tehran, Iran, between May 2021 and November 2022. After obtaining written informed consent, demographic data and spirometry measurements were collected to classify COPD severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. Venous blood samples were analyzed for eosinophil counts, categorizing patients into groups with counts below or above 300 cells/μL. Participants were followed for six months to record clinical outcomes, including mortality, hospitalizations, and outpatient visits related to COPD exacerbations. The study’s primary focus was to assess the impact of ICS on exacerbation rates stratified by eosinophil levels, aiming to evaluate eosinophil count as a biomarker for treatment responsiveness and to inform personalized COPD management. Results: In a population of COPD patients who underwent ICS, the results indicated that patients with eosinophil counts higher than 300 cells/μL, compared to those with lower counts, demonstrated significantly fewer hospitalization rates (unadjusted B: -0.52 and adjusted B: -0.55). Similarly, the relationship between elevated eosinophil counts and outpatient visit frequency showed significant negative associations (unadjusted B: -1.82 and adjusted B: 1.88). However, in terms of six-month outcomes (recovery versus death), no statistically significant differences were observed between the two groups. Conclusion: These findings suggest that blood eosinophil counts ≥300 cells/μL are associated with a pronounced reduction in severe COPD exacerbations among patients treated with ICS. This supports the use of eosinophil levels as a practical biomarker to guide ICS therapy, enabling more targeted, personalized treatment strategies that optimize clinical outcomes in COPD management.
- Open Access
- 29 April 2025
- Published by Brieflands in Archives of Neuroscience
- Vol. 12 (2)
Incidence and Risk Factors of Delirium in COPD Patient in Intensive Care Unit
Background: Delirium is an abnormal mental state that, in some patients, is associated with disturbances in sleep cycles, orientation, and perception. Objectives: The aim of this study was to determine the incidence and risk factors of delirium in patients with chronic obstructive pulmonary disease (COPD) in the intensive care unit (ICU). Methods: In this registry study conducted in Iran, data from 74 COPD patients aged over 18 years, without dementia, and hospitalized in the internal ICU for more than 2 days were analyzed. The registry checklist included information on gender, infection, fever, serum creatinine ≥ 1.2 mg/dL, hypertension, diabetes mellitus, smoking, chronic renal failure, discharge destination, age, number of days in the hospital, Glasgow Coma Scale (GCS) score, and partial pressure of oxygen (PaO2). Data analysis was performed using SPSS version 18 software. Results: Of the 74 patients examined, 19 (25.7%) experienced delirium, while 55 (74.3%) showed no symptoms of delirium. The incidence of delirium was higher in patients with a history of infection and fever. Delirium was significantly associated with older age, lower GCS scores, and lower PaO2 levels (P < 0.05). In the delirium group, the mean age was 73.21 ± 7.64 years, the length of stay (LOS) in the hospital was 27.42 ± 11.57 days, the GCS score was 6.10 ± 0.87, and the PaO2 was 75.26 ± 3.42 mmHg. In contrast, in the non-delirium group, the mean age was 66.25 ± 11.12 years, the LOS was 23.87 ± 8.16 days, the GCS score was 10.65 ± 2.61, and the PaO2 was 82.12 ± 4.93 mmHg. Conclusions: The incidence of delirium in COPD patients in the ICU was high. Identifying effective and aggravating factors is crucial, and necessary measures should be implemented to reduce the occurrence of delirium.
- 29 April 2025
- Published by Brieflands in Archives of Neuroscience
- Vol. 12 (2)
Open AccessIncidence and Risk Factors of Delirium in COPD Patient in Intensive Care Unit
Background: Delirium is an abnormal mental state that, in some patients, is associated with disturbances in sleep cycles, orientation, and perception. Objectives: The aim of this study was to determine the incidence and risk factors of delirium in patients with chronic obstructive pulmonary disease (COPD) in the intensive care unit (ICU). Methods: In this registry study conducted in Iran, data from 74 COPD patients aged over 18 years, without dementia, and hospitalized in the internal ICU for more than 2 days were analyzed. The registry checklist included information on gender, infection, fever, serum creatinine ≥ 1.2 mg/dL, hypertension, diabetes mellitus, smoking, chronic renal failure, discharge destination, age, number of days in the hospital, Glasgow Coma Scale (GCS) score, and partial pressure of oxygen (PaO2). Data analysis was performed using SPSS version 18 software. Results: Of the 74 patients examined, 19 (25.7%) experienced delirium, while 55 (74.3%) showed no symptoms of delirium. The incidence of delirium was higher in patients with a history of infection and fever. Delirium was significantly associated with older age, lower GCS scores, and lower PaO2 levels (P < 0.05). In the delirium group, the mean age was 73.21 ± 7.64 years, the length of stay (LOS) in the hospital was 27.42 ± 11.57 days, the GCS score was 6.10 ± 0.87, and the PaO2 was 75.26 ± 3.42 mmHg. In contrast, in the non-delirium group, the mean age was 66.25 ± 11.12 years, the LOS was 23.87 ± 8.16 days, the GCS score was 10.65 ± 2.61, and the PaO2 was 82.12 ± 4.93 mmHg. Conclusions: The incidence of delirium in COPD patients in the ICU was high. Identifying effective and aggravating factors is crucial, and necessary measures should be implemented to reduce the occurrence of delirium.
- Open Access
- 1 March 2025
- Published by Brieflands in Archives of Neuroscience
- Vol. 12 (2)
Clinical Outcomes of Patients with Parkinson’s Disease with Ventilator Dependency
Background: Parkinson's disease (PD) is a progressive neurological disorder that causes damage to dopamine neurons in the substantia nigra of the brain. Objectives: Considering the complications caused by PD, this study was conducted to determine the clinical outcomes of patients with PD who are ventilator-dependent. Methods: This case-control study (registry data) was conducted among hospitalized patients with underlying PD and a control group. The study included intubated patients who were definitively diagnosed with PD. Researchers completed patient data according to a registry checklist, which included demographic information and registry data. After collecting the information, the data were entered into SPSS version 16 software for analysis. Results: In this study, 16 patients with PD were placed in the case group, and 36 patients with other neurological disorders hospitalized in the ICU were placed in the control group. The findings showed a comparison of clinical and laboratory indicators between the PD group and the control group. According to the findings, there was no significant difference in all variables, except for PaO2/FiO2 and HCO3- (mmol/L), between the two groups (P > 0.05). Additionally, factors such as renal dialysis, chronic respiratory disease, and leukemia/myeloma were associated with patient mortality (P < 0.05). The APACHE III score was also associated with mortality (P = 0.001). Conclusions: Given the differences in clinical indicators between patients with PD and the control group, it is suggested that these differences be considered in providing clinical care to these patients.
- 1 March 2025
- Published by Brieflands in Archives of Neuroscience
- Vol. 12 (2)
Open AccessClinical Outcomes of Patients with Parkinson’s Disease with Ventilator Dependency
Background: Parkinson's disease (PD) is a progressive neurological disorder that causes damage to dopamine neurons in the substantia nigra of the brain. Objectives: Considering the complications caused by PD, this study was conducted to determine the clinical outcomes of patients with PD who are ventilator-dependent. Methods: This case-control study (registry data) was conducted among hospitalized patients with underlying PD and a control group. The study included intubated patients who were definitively diagnosed with PD. Researchers completed patient data according to a registry checklist, which included demographic information and registry data. After collecting the information, the data were entered into SPSS version 16 software for analysis. Results: In this study, 16 patients with PD were placed in the case group, and 36 patients with other neurological disorders hospitalized in the ICU were placed in the control group. The findings showed a comparison of clinical and laboratory indicators between the PD group and the control group. According to the findings, there was no significant difference in all variables, except for PaO2/FiO2 and HCO3- (mmol/L), between the two groups (P > 0.05). Additionally, factors such as renal dialysis, chronic respiratory disease, and leukemia/myeloma were associated with patient mortality (P < 0.05). The APACHE III score was also associated with mortality (P = 0.001). Conclusions: Given the differences in clinical indicators between patients with PD and the control group, it is suggested that these differences be considered in providing clinical care to these patients.
- Open Access
- 16 November 2024
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11, e43744
Evaluation of fractional exhaled nitric oxide in patients with chronic cough based on causes
Introduction: Cough is a common complaint in clinics, and diagnosing sub-acute or chronic cough is very important. Objectives: This study aimed to evaluate the association between fractional exhaled nitric oxide (FeNO) and causes of chronic cough and also, answer to this question that can we use FeNo for the diagnosis of the causes of chronic cough. Patients and Methods: In this descriptive-analytical cross-sectional study, 90 patients with a complaint of cough lasting more than three weeks were assessed. Spirometry and a methacholine stimulation test, complete blood count (CBC) serum IgE-diff, and FeNO were performed for all patients. Results: The mean age of the patients was 48.5±11.41 years, and 56.7% were male. Regarding medical history, 22.4% had asthma, 6.7% had chronic obstructive pulmonary disease (COPD), and 68.9% had no history of respiratory disease. Gastric reflux was detected in 42.2%. The mean duration of the onset of cough in the studied patients was 25.6±38.6 months. There was a significant correlation between the FeNO and IgE levels (P=0.048). The mean level of FeNO was 25±6.7 in patients with asthma, 57.3 ±18.7 in patients with COPD, and 22.8±1.6 in patients without a history of respiratory disease (P=0.002). Conclusion: This study’s findings showed a positive and significant correlation between FeNO and IgE. In addition, the FeNO level was significantly different based on the spirometry findings and respiratory diseases of asthma and COPD.
- 16 November 2024
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11, e43744
Open AccessEvaluation of fractional exhaled nitric oxide in patients with chronic cough based on causes
Introduction: Cough is a common complaint in clinics, and diagnosing sub-acute or chronic cough is very important. Objectives: This study aimed to evaluate the association between fractional exhaled nitric oxide (FeNO) and causes of chronic cough and also, answer to this question that can we use FeNo for the diagnosis of the causes of chronic cough. Patients and Methods: In this descriptive-analytical cross-sectional study, 90 patients with a complaint of cough lasting more than three weeks were assessed. Spirometry and a methacholine stimulation test, complete blood count (CBC) serum IgE-diff, and FeNO were performed for all patients. Results: The mean age of the patients was 48.5±11.41 years, and 56.7% were male. Regarding medical history, 22.4% had asthma, 6.7% had chronic obstructive pulmonary disease (COPD), and 68.9% had no history of respiratory disease. Gastric reflux was detected in 42.2%. The mean duration of the onset of cough in the studied patients was 25.6±38.6 months. There was a significant correlation between the FeNO and IgE levels (P=0.048). The mean level of FeNO was 25±6.7 in patients with asthma, 57.3 ±18.7 in patients with COPD, and 22.8±1.6 in patients without a history of respiratory disease (P=0.002). Conclusion: This study’s findings showed a positive and significant correlation between FeNO and IgE. In addition, the FeNO level was significantly different based on the spirometry findings and respiratory diseases of asthma and COPD.
- Open Access
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 10 (1) , e25180
Assessing predictors of pulmonary sequel in COVID-19 patients through lung CT imaging; a two-month comprehensive evaluation
Introduction: The emergence of COVID-19 has resulted in an unprecedented global health crisis. While acute respiratory symptoms are well-documented, there is growing concern regarding the long-term pulmonary effects in survivors. Objectives: This study aimed to evaluate the pulmonary sequel of COVID-19 patients referred to Imam Hossein Hospital, Tehran, Iran, in 2022. Patients and Methods: This longitudinal study involved 180 patients who recovered from COVID-19 at Imam Hossein Hospital in 2022, selected based on confirmed diagnoses and resolution of acute symptoms. Data were collected through a demographic questionnaire and a clinical checklist. Participants were followed for two months, during which lung involvement was categorized as clear or non-clear, allowing for the evaluation of associations between demographic and clinical data with computed tomography (CT) outcomes. Results: Results indicated a statistically significant correlation between clinical findings, including lung involvement exceeding 30%, intensive care unit (ICU) admission necessity, intubation status, and prolonged hospitalization duration in patients with clear or non-clear pulmonary status. Lung involvement greater than 30% and longer hospitalization duration were identified as independent predictors of adverse pulmonary outcomes, with odds ratios of 2.30 and 2.47, respectively. Conclusion: The study highlights a significant relationship between clinical findings and pulmonary outcomes in COVID-19 patients, particularly emphasizing that lung involvement exceeding 30% and prolonged hospitalization are critical independent predictors of adverse respiratory complications.
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 10 (1) , e25180
Open AccessAssessing predictors of pulmonary sequel in COVID-19 patients through lung CT imaging; a two-month comprehensive evaluation
Introduction: The emergence of COVID-19 has resulted in an unprecedented global health crisis. While acute respiratory symptoms are well-documented, there is growing concern regarding the long-term pulmonary effects in survivors. Objectives: This study aimed to evaluate the pulmonary sequel of COVID-19 patients referred to Imam Hossein Hospital, Tehran, Iran, in 2022. Patients and Methods: This longitudinal study involved 180 patients who recovered from COVID-19 at Imam Hossein Hospital in 2022, selected based on confirmed diagnoses and resolution of acute symptoms. Data were collected through a demographic questionnaire and a clinical checklist. Participants were followed for two months, during which lung involvement was categorized as clear or non-clear, allowing for the evaluation of associations between demographic and clinical data with computed tomography (CT) outcomes. Results: Results indicated a statistically significant correlation between clinical findings, including lung involvement exceeding 30%, intensive care unit (ICU) admission necessity, intubation status, and prolonged hospitalization duration in patients with clear or non-clear pulmonary status. Lung involvement greater than 30% and longer hospitalization duration were identified as independent predictors of adverse pulmonary outcomes, with odds ratios of 2.30 and 2.47, respectively. Conclusion: The study highlights a significant relationship between clinical findings and pulmonary outcomes in COVID-19 patients, particularly emphasizing that lung involvement exceeding 30% and prolonged hospitalization are critical independent predictors of adverse respiratory complications.
- 10 December 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (5) , 1156-1166
CRISPR-Cas9-mediated gene therapy in lung cancer
As the largest cause of cancer-related deaths worldwide, pulmonary cancer is the most common form of the disease. Several genetic, epigenetic, and environmental factors come into play during the multi-step mechanism of tumorigenesis. The heterogeneity that makes discovering successful therapeutics for pulmonary cancer problematic is significantly influenced by the epigenetic landscape, including DNA methylation, chromatin architecture, histone modifications, and noncoding RNA control. Clinical activity of epigenetic-targeted medicines has been reported in hematological tumors, and these compounds may also have therapeutic effects in solid tumors. Over the course of the past few years, some researchers have successfully modified the expression of genes in cells using the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated proteins) technique. The utilization of this technology allows for the induction of site-specific mutagenesis, epigenetic alterations, and the regulation of gene expression. This study will present an overview of the primary epigenetic alterations seen in pulmonary cancer, as well as a summary of therapeutic implications for targeting epigenetics in the management of pulmonary cancer, with a particular emphasis on the technique known as CRISPR/Cas9.
- 10 December 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (5) , 1156-1166
CRISPR-Cas9-mediated gene therapy in lung cancer
As the largest cause of cancer-related deaths worldwide, pulmonary cancer is the most common form of the disease. Several genetic, epigenetic, and environmental factors come into play during the multi-step mechanism of tumorigenesis. The heterogeneity that makes discovering successful therapeutics for pulmonary cancer problematic is significantly influenced by the epigenetic landscape, including DNA methylation, chromatin architecture, histone modifications, and noncoding RNA control. Clinical activity of epigenetic-targeted medicines has been reported in hematological tumors, and these compounds may also have therapeutic effects in solid tumors. Over the course of the past few years, some researchers have successfully modified the expression of genes in cells using the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated proteins) technique. The utilization of this technology allows for the induction of site-specific mutagenesis, epigenetic alterations, and the regulation of gene expression. This study will present an overview of the primary epigenetic alterations seen in pulmonary cancer, as well as a summary of therapeutic implications for targeting epigenetics in the management of pulmonary cancer, with a particular emphasis on the technique known as CRISPR/Cas9.
- Open Access
- 18 January 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-3
Evaluation of the efficacy and safety of inhaled magnesium sulphate in combination with standard treatment in patients with moderate or severe COVID-19: A structured summary of a study protocol for a randomised controlled trial
Objectives: Basic and clinical studies have shown that magnesium sulphate ameliorates lung injury and controls asthma attacks by anti-inflammatory and bronchodilatory effects. Both intravenous and inhaled magnesium sulphate have a clinical impact on acute severe asthma by inhibition of airway smooth muscle contraction. Besides, magnesium sulphate can dilate constricted pulmonary arteries and reduce pulmonary artery resistance. However, it may affect systemic arteries when administered intravenously. A large number of patients with covid-19 admitted to the hospital suffer from pulmonary involvement. COVID-19 can cause hypoxia due to the involvement of the respiratory airways and parenchyma along with circulatory impairment, which induce ventilation-perfusion mismatch. This condition may result in hypoxemia and low arterial blood oxygen pressure and saturation presented with some degree of dyspnoea and shortness of breath. Inhaled magnesium sulphate as a smooth muscle relaxant (natural calcium antagonist) can cause both bronchodilator and consequently vasodilator effects (via a direct effect on alveolar arterioles in well-ventilated areas) in the respiratory tract. We aim to investigate if inhaled magnesium sulphate as adjuvant therapy to standard treatment can reduce ventilation-perfusion mismatch in the respiratory tract and subsequently improve arterial oxygen saturation in hospitalized patients with COVID-19. Trial design: A multi-centre, open-label, randomised controlled trial (RCT) with two parallel arms design (1:1 ratio) Participants: Patients aged 18-80 years hospitalized at Masih Daneshvari Hospital and Shahid Dr. Labbafinejad hospital in Tehran and Shahid Sadoughi Hospital in Yazd will be included if they meet the inclusion criteria of the study. Inclusion criteria are defined as 1. Confirmed diagnosis of SARS-CoV-2 infection based on polymerase chain reaction (PCR) of nasopharyngeal secretions or clinical manifestations along with chest computed tomography (chest CT) scan 2. Presenting with moderate or severe COVID-19 lung involvement confirmed with chest CT scan and arterial oxygen saturation below 93% 3. Length of hospital stay ≤48 hours. Patients with underlying cardiovascular diseases including congestive heart failure, bradyarrhythmia, heart block, the myocardial injury will be excluded from the study. Intervention and comparator: Participants will be randomly divided into two arms. Patients in the intervention arm will be given both standard treatment for COVID-19 (according to the national guideline) and magnesium sulphate (5 cc of a 20% injectable vial or 2 cc of a 50% injectable vial will be diluted by 50 cc distilled water and nebulized via a mask) every eight hours for five days. Patients in the control (comparator) arm will only receive standard treatment for COVID-19. Main outcomes: Improvement of respiratory function and symptoms including arterial blood oxygen saturation, dyspnoea (according to NYHA functional classification), and cough within the first five days of randomization. Randomisation: Block randomisation will be used to allocate eligible patients to the study arms (in a 1:1 ratio). Computer software will be applied to randomly select the blocks. Blinding (masking): The study is an open-label RCT without blinding. Numbers to be randomised (sample size): The trial will be performed on 100 patients who will be randomly divided into two arms of control (50) and intervention (50). Trial Status: The protocol is Version 5.0, January 05, 2021. Recruitment of the participants started on July 30, 2020, and it is anticipated to be completed by February 28, 2021. Trial registration: The trial was registered in the Iranian Registry of Clinical Trials (IRCT) on July 28, 2020. It is available on https://en.irct.ir/trial/49879. The registration number is IRCT20191211045691N1. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
- 18 January 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-3
Open AccessEvaluation of the efficacy and safety of inhaled magnesium sulphate in combination with standard treatment in patients with moderate or severe COVID-19: A structured summary of a study protocol for a randomised controlled trial
Objectives: Basic and clinical studies have shown that magnesium sulphate ameliorates lung injury and controls asthma attacks by anti-inflammatory and bronchodilatory effects. Both intravenous and inhaled magnesium sulphate have a clinical impact on acute severe asthma by inhibition of airway smooth muscle contraction. Besides, magnesium sulphate can dilate constricted pulmonary arteries and reduce pulmonary artery resistance. However, it may affect systemic arteries when administered intravenously. A large number of patients with covid-19 admitted to the hospital suffer from pulmonary involvement. COVID-19 can cause hypoxia due to the involvement of the respiratory airways and parenchyma along with circulatory impairment, which induce ventilation-perfusion mismatch. This condition may result in hypoxemia and low arterial blood oxygen pressure and saturation presented with some degree of dyspnoea and shortness of breath. Inhaled magnesium sulphate as a smooth muscle relaxant (natural calcium antagonist) can cause both bronchodilator and consequently vasodilator effects (via a direct effect on alveolar arterioles in well-ventilated areas) in the respiratory tract. We aim to investigate if inhaled magnesium sulphate as adjuvant therapy to standard treatment can reduce ventilation-perfusion mismatch in the respiratory tract and subsequently improve arterial oxygen saturation in hospitalized patients with COVID-19. Trial design: A multi-centre, open-label, randomised controlled trial (RCT) with two parallel arms design (1:1 ratio) Participants: Patients aged 18-80 years hospitalized at Masih Daneshvari Hospital and Shahid Dr. Labbafinejad hospital in Tehran and Shahid Sadoughi Hospital in Yazd will be included if they meet the inclusion criteria of the study. Inclusion criteria are defined as 1. Confirmed diagnosis of SARS-CoV-2 infection based on polymerase chain reaction (PCR) of nasopharyngeal secretions or clinical manifestations along with chest computed tomography (chest CT) scan 2. Presenting with moderate or severe COVID-19 lung involvement confirmed with chest CT scan and arterial oxygen saturation below 93% 3. Length of hospital stay ≤48 hours. Patients with underlying cardiovascular diseases including congestive heart failure, bradyarrhythmia, heart block, the myocardial injury will be excluded from the study. Intervention and comparator: Participants will be randomly divided into two arms. Patients in the intervention arm will be given both standard treatment for COVID-19 (according to the national guideline) and magnesium sulphate (5 cc of a 20% injectable vial or 2 cc of a 50% injectable vial will be diluted by 50 cc distilled water and nebulized via a mask) every eight hours for five days. Patients in the control (comparator) arm will only receive standard treatment for COVID-19. Main outcomes: Improvement of respiratory function and symptoms including arterial blood oxygen saturation, dyspnoea (according to NYHA functional classification), and cough within the first five days of randomization. Randomisation: Block randomisation will be used to allocate eligible patients to the study arms (in a 1:1 ratio). Computer software will be applied to randomly select the blocks. Blinding (masking): The study is an open-label RCT without blinding. Numbers to be randomised (sample size): The trial will be performed on 100 patients who will be randomly divided into two arms of control (50) and intervention (50). Trial Status: The protocol is Version 5.0, January 05, 2021. Recruitment of the participants started on July 30, 2020, and it is anticipated to be completed by February 28, 2021. Trial registration: The trial was registered in the Iranian Registry of Clinical Trials (IRCT) on July 28, 2020. It is available on https://en.irct.ir/trial/49879. The registration number is IRCT20191211045691N1. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.